|
Gregory B. Lawless, Ph.D. is the co-founder and managing partner of Collins Mabry & Co., a strategic advisory firm for the life sciences industry. Previously, he served as President and Chief Executive Officer at Cygnus, Inc. where he started the R&D program that lead to the development of the first FDA-approved non-invasive glucose-monitoring device for patient use, the GlucoWatch(R) Biographer. Prior to that, he served as President and Chief Operating Officer at Chiron Corporation where he was instrumental in leading the company to profitability. He received his B.S. degree in pharmacy from Fordham University, his MS degree in analytical chemistry from St. John's University and his Ph.D. in physical organic chemistry in Temple University.
| 